Novartis gets EU OK for first-ever copycat of biotech drug

Share this article:
The European Commission has granted Novartis’ Sandoz unit the first-ever authorization to market a copycat version of a biotech medicine. Novartis said Tuesday it received approval for Omnitrope, a recombinant human growth hormone. Omnitrope is an equivalent version of Pfizer’s human growth hormone Genotropin and Serono’s Saizen. Novartis is expected to market the product soon, with Germany and Austria being the first markets in Europe where the drug will be available. Omnitrope is currently on the market in Australia, where it was launched in 2005.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.